It's a different business. You're selling to a different market; you're dealing with a different distribution system. And the big thing that we have in Canada is an automatic substitution policy at the provincial level, which says that the lowest price gets the market. So what happens to us is that as we approach patent expiry, if we are to drop our price, we have to make sure that we indeed have the lowest price to get that business. Even with that cost structure, we found that we could not lower it enough to compete with the generics, so we chose not to get into that business.
There have been examples where we've licensed out products. In certain circumstances, we've licensed out with generics to do that. But again, you only get a fraction of the revenue. So that's why you see us, by and large, in the innovation business, not the generic business.